Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Machann, W; Breunig, F; Weidemann, F; Sandstede, J; Hahn, D; Kostler, H; Neubauer, S; Wanner, C; Beer, M.
Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A
Eur J Heart Fail. 2011; 13(3):278-283
Doi: 10.1093/eurjhf/hfq211
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Beer Meinrad
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Aims In vitro studies have shown impairment of energy metabolism in cardiac fibroblasts from Fabry patients. A recent in vivo study reported an association between cardiac energy metabolism and increased myocardial mass in Fabry patients. We therefore assessed possible disturbances of cardiac energy metabolism in Fabry patients by in vivo P-31-MR-spectroscopy. Additionally, the effect of enzyme replacement therapy (ERT) on cardiac energetics was tested. Methods and results Twenty-three patients (41 +/- 9 years; 10 females) with genetically proven Fabry disease were examined with a 1.5 T Scanner, and compared with an age-matched healthy control group. Eight patients underwent ERT and had follow-up examinations after 3 and 14 months. The high-energy phosphate molecules phosphocreatine (PCr) and adenosine triphosphate (ATP) were quantified in localized 31P-spectra by SLOOP (spectral localization with optimum point spread function). Cine-and late gadolinium enhancement (LGE) studies were also performed. When compared with healthy controls, Fabry patients demonstrated reduced PCr- (6.1 +/- 1.9 vs. 8.8 +/- 2.6 mmol/kg; P = 0.003) and ATP concentrations (3.9 +/- 1.5 vs. 4.6 +/- 1.0 mmol/kg; P = 0.048). During ERT, PCr concentrations increased (7.1 +/- 1.5 mmol/kg vs. 6.1 +/- 1.9; P < 0.05) and left ventricular mass decreased (215 +/- 55 vs. 185 +/- 45 g; P = 0.012). Disturbances in cardiac energetics were not correlated to the presence or absence of cardiac fibrosis on LGE. Conclusion Cardiac energy metabolism is disturbed in Fabry disease; this may play an important role in the pathogenesis of Fabry cardiomyopathy. Enzyme replacement therapy ameliorates energetic depression.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Case-Control Studies -
- Energy Metabolism - drug effects
- Enzyme Replacement Therapy - methods
- Fabry Disease - metabolism Fabry Disease - therapy
- Female -
- Follow-Up Studies -
- Humans -
- Magnetic Resonance Spectroscopy -
- Male -
- Middle Aged -
- Myocardium - metabolism Myocardium - pathology
- alpha-Galactosidase - genetics alpha-Galactosidase - pharmacology alpha-Galactosidase - therapeutic use
- Find related publications in this database (Keywords)
- Cardiomyopathy
- Hypertrophy
- Enzyme replacement therapy
- Magnetic resonance spectroscopy
- Cardiac high-energy phosphates